AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Disease
VILNIUS, LT / ACCESS Newswire / July 15, 2025 / AATec Medical GmbH ("AATec"), a biotech company developing a multi-product platform for the treatment of respiratory diseases, and Northway Biotech ("Northway Biotech" or "NBT"), a global Contract Development and Manufacturing Organization (CDMO), today announced a partnership for manufacturing process development and analytical development of AATec's lead product candidate, ATL-105, a proprietary, inhaled therapy based on recombinant alpha-1 antitrypsin (AAT) for non-cystic fibrosis bronchiectasis (NCFB).
Under the agreement, Northway Biotech will leverage its expertise in biologics manufacturing to develop and scale the production process for ATL-105 using the Pichia pastoris expression system.
"With this partnership, we are establishing a robust and scalable production process for ATL- 105, laying the foundation for consistent quality for clinical development and commercial use," says Rüdiger Jankowsky, PhD, co-founder and CEO of AATec, and adds: "ATL-105 represents a new generation of inhaled biologics, combining anti-protease, anti-inflammatory, and antiinfective properties in one molecule. Delivered directly to the lungs, it enables fast, targeted action with minimal systemic exposure. We believe ATL-105 can redefine care in respiratory diseases with high medical need, such as non-CF bronchiectasis."
"We are excited to support AATec in progressing towards clinical trials", shares Prof. Vladas Algirdas Bumelis, CEO and Chairman of Northway Biotech. "AATec is advancing a promising therapeutic solution addressing significant unmet medical needs, supported by a highly capable and dedicated team. With our decades of expertise in microbial systems, we are well-positioned to scale this program efficiently and deliver quality at every step."
"We have recognized the opportunity to support a program that could meaningfully advance care for patients with respiratory diseases," adds André Markmann, PhD, VP of Business Development at Northway Biotech. "Inhaled protein therapies are gaining significant traction, and ATL-105 stands out as one of the most promising approaches in this area."
AATec develops ATL-105 to treat NCFB, a chronic inflammatory respiratory condition which affects millions of people worldwide. This debilitating disease is marked by dilated bronchi, persistent inflammation, frequent airway infections and impaired mucus clearance. In addition to NCFB, ATL-105 has therapeutic potential for a broader range of inflammatory and infectious respiratory diseases, such as COPD, ARDS and other indications, reflecting the versatility of its anti-inflammatory, immunomodulatory, and anti-infective properties.
About AATec Medical
AG AATec Medical GmbH is a biotechnology company developing a product platform based on a novel recombinant version of alpha-1 antitrypsin (AAT) for the treatment of respiratory inflammatory diseases, airway infections and rare diseases. The company has successfully demonstrated proof-of-principle in several indications and is currently preparing for a proof-ofconcept clinical trial with the first product candidate ATL-105 for inhaled application in non-CF bronchiectasis. AATec was founded by a seasoned interdisciplinary team with long-standing experience in clinical research, biopharmaceutical development and product industrialization. For further information, please visit https://www.aatec-medical.com/ and follow AATec on LinkedIn.
About Northway Biotech
Northway Biotech is a leading CDMO specializing in protein-based biologics and gene therapies, offering comprehensive, end-to-end biopharmaceutical development and manufacturing services. With deep expertise in cell line development, process optimization, and cGMP manufacturing, Northway Biotech supports programs from early-stage development through to commercial production. Founded in 2004, the privately held company operates state-of-the-art facilities in Lithuania and the United States, delivering high-quality, compliant solutions tailored to each client's unique needs. For further information, please visit https://www.northwaybiotech.com.
Northway Biotech Contact:
Prof. Vladas Algirdas BumelisCEO and Chairman of the Boardvladas.bumelis@northwaybiotech.com
AATec Medical Contact:
Dr. Rüdiger Jankowsky, CEOinfo@aatec-medical.com
Media Contact:
MC ServicesKatja Arnold, Julia von Hummelaatec-medical@mc-services.euPhone: +49 (0)89 2102280
SOURCE: Northway Biotech
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
WebMD
12 hours ago
- WebMD
Brinsupri: First Once-Daily Tablet for Non-Cystic Fibrosis Bronchiectasis
What Is Brinsupri, and Why Does It Matter? Brinsupri (brensocatib) is a new oral medicine approved to treat a long-term lung disease known as non-cystic fibrosis bronchiectasis (NCFB) in adults and children ages 12 or older. It works by blocking an enzyme called DPP1, which normally activates certain proteins in white blood cells that cause inflammation in the lungs. By stopping this process, Brinsupri may help reduce lung damage and lower the number of flare-ups that result in worsening cough, increased mucus, shortness of breath, and fatigue that you may experience with NCFB. Brinsupri is the first and only medicine approved by the FDA that is made specifically for NCFB, which affects about 500,000 people in the U.S. and many more around the world. NCFB widens and damages the airways in your lungs, making it harder to clear mucus. This can lead to trouble breathing and frequent lung infections that often require antibiotics or hospital care while also affecting a person's emotional health and overall well-being. Until now, there were no approved treatments that directly targeted the inflammation behind this disease. Why Was It Approved? Brinsupri was approved because studies showed it was safe and effective in reducing the yearly number of flare-ups in people with NCFB. In one study, people who took Brinsupri (10 milligrams or 25 milligrams) had about 20% fewer flare-ups over a year than those who took a placebo. It also helped delay the time to the first flare-up and increased the number of people who didn't have any flare-ups during the study period. The higher dose also slowed down the worsening of lung function. The most common side effects included upper respiratory tract infections, headaches, skin rashes, dry or thickened skin, and high blood pressure, along with gum or dental problems. Less common side effects included changes in liver test results and thinning hair. The studies included adults and children aged 12 and older. Brinsupri has not been studied in children under 12, so it's not known if it's safe or effective for that age group. What Do I Need to Know? Brinsupri is a tablet you take once a day. It comes in 10-milligram and 25-milligram strengths and can be taken with or without food. If you miss a dose, just take your next dose at the usual time the next day. Don't take two doses at once to make up for a missed one. This medicine is now available in the U.S. through a specialty pharmacy network. Talk to your health care provider to see if Brinsupri is right for you, especially if you have skin or dental issues. Brinsupri may raise the risk for skin, gum, or tooth problems, so regular checkups with a dermatologist and dentist are a good idea. It is not known if Brinsupri affects how well certain vaccines work. Talk to your health care provider if you are planning to take a live, attenuated vaccine before or during your treatment. Let your health care provider know about all the medicines you take. Brinsupri may interact with other drugs, especially those that affect how your liver processes medicine. There's no safety information yet about using Brinsupri during pregnancy or while breastfeeding, so be sure to talk with your health care provider if you are pregnant, planning to become pregnant, or nursing.
Associated Press
a day ago
- Associated Press
CardoMax Acquired by Cardone Ventures, Marking a New Era in High-Performance Nutrition
Miami, FL August 12, 2025 --( )-- CardoMax, the innovative liquid-based supplement company founded by former Navy SEALs, has been acquired by Cardone Ventures, the leading business growth and investment firm founded by Grant Cardone and Brandon Dawson. This acquisition marks a significant step in the evolution of performance nutrition, bringing CardoMax's proprietary AAT® Accelerated Absorption Technology® under the umbrella of Cardone Ventures' expanding health and wellness portfolio. CardoMax's single-serve, liquid-based supplements have revolutionized the industry by delivering nutrients up to 20 times faster and 3 times more efficiently than traditional supplement forms. Initially, CardoMax partnered with 10X Health System, a subsidiary of Cardone Ventures, by white-labeling its unique formulations. The success of that collaboration led to this acquisition, ensuring deeper integration and wider accessibility for consumers seeking elite performance and peak vitality. 'From day one, our mission at CardoMax has been to provide people with the most efficient and effective way to fuel their bodies,' said Sean Matson, Co-Founder & CEO of CardoMax. 'By joining forces with Cardone Ventures, we're taking this mission to the next level—scaling faster, innovating further, and ensuring our game-changing formulas reach even more people.' With this acquisition, Cardone Ventures is doubling down on its commitment to disrupt the health and wellness space with high-impact, results-driven solutions. 'CardoMax represents the kind of innovative thinking and market leadership that aligns perfectly with our vision,' said Brandon Dawson, CEO of Cardone Ventures. 'By bringing them fully into the Cardone Ventures ecosystem, we're not just investing in a brand—we're investing in a movement that empowers people to take control of their health with the highest-quality supplements on the market.' The integration of CardoMax's proprietary technology into 10X Health System and beyond will expand its reach, accelerate product development, and drive new advancements in performance supplementation. Together, CardoMax and Cardone Ventures are setting a new standard for next-level health, energy, and performance. For more information, visit and Disclaimer: The statements herein have not been evaluated by the Food and Drug Administration. The products mentioned herein are not intended to diagnose, treat, cure, or prevent any disease. About CardoMax Founded by former Navy SEALs, CardoMax is a pioneer in liquid-based supplements designed for maximum absorption and efficiency. Using AAT® Accelerated Absorption Technology®, CardoMax's formulas deliver faster, cleaner, and more effective performance-enhancing nutrition. About Cardone Ventures & 10X Health Systems Cardone Ventures, co-founded by Brandon and Natalie Dawson, in partnership with Grant Cardone, is a business growth firm dedicated to helping entrepreneurs scale and optimize their businesses through strategic investments and leadership development. 10X Health Systems, a subsidiary of Cardone Ventures, is on a mission to maximize human performance through precision genetic testing, personalized health optimization plans, and innovative supplement solutions. By combining cutting-edge science with elite business strategy, Cardone Ventures and 10X Health Systems are redefining what's possible in the world of entrepreneurial health and high-performance living. Contact Information: CardoMax Lisa De Rosa 480-376-1990 Contact via Email Read the full story here: CardoMax Acquired by Cardone Ventures, Marking a New Era in High-Performance Nutrition Press Release Distributed by
Yahoo
2 days ago
- Yahoo
New Irish Healthtech Firm Phyxiom Set to Transform Asthma and COPD Management
Groundbreaking research by Professor Richard Costello leads to innovative digital health platform DUBLIN, August 12, 2025--(BUSINESS WIRE)--Phyxiom, a pioneering digital healthcare company, today announced its official launch, bringing transformative technology developed through extensive clinical research led by globally recognised respiratory specialist, Professor Richard Costello (RCSI University of Medicine and Health Sciences and Beaumont Hospital). Built upon groundbreaking studies published in Lancet Respiratory Medicine and validated by health economists, Phyxiom's platform provides clinicians with precise, real-time data to significantly enhance asthma and Chronic Obstructive Pulmonary Disease (COPD) management. Co-founded by experienced tech executive Grace O'Donnell as Chief Executive Officer and healthcare professional Elaine Mac Hale as Clinical Operations Director, along with Prof Costello, Phyxiom is a spin-out company from RCSI. Based on a strong foundational IP portfolio developed under an Enterprise Ireland (EI) Commercialisation Fund award the company has recently achieved EI High Potential Start- Up (HPSU) status. O'Donnell and Mac Hale lead Phyxiom's day-to-day operations, driving forward its mission to revolutionise respiratory healthcare through advanced digital solutions. Professor Richard Costello, Chief Medical Officer at Phyxiom and Professor of Respiratory Medicine at RCSI, explained the science behind the innovation: "Our research, spanning over a decade, has conclusively demonstrated that digitally-informed treatment significantly reduces medication use, prevents unnecessary hospitalisations, and ultimately lowers healthcare costs. By providing clinicians with objective, real-time insights into lung function and medication adherence, Phyxiom fundamentally improves diagnosis accuracy and treatment outcomes." Phyxiom's technology is already operational across 13 Health Service Executive (HSE) asthma clinics in Ireland, processing nearly 350 patients to date, with plans to expand further and engage Irish private health insurers in 2025. Grace O'Donnell, CEO, said: "Elaine and I are incredibly proud to lead this exciting RCSI spin-out company into the commercial market. We are passionate about using Richard's groundbreaking research as the foundation to deliver transformative, patient-centric healthcare solutions, significantly improving quality of life for patients suffering from uncontrolled asthma and COPD." Elaine Mac Hale, Clinical Operations Director, added: "Phyxiom seamlessly integrates into existing healthcare systems, ensuring minimal disruption to clinicians' workflows. Our evidence-based approach empowers healthcare providers with the insights needed to deliver personalised, effective, and efficient patient care." Following its successful Irish rollout, Phyxiom is expanding into the UK market in H1 2026 and plans a US launch in 2027, supported by established partnerships and integration with leading electronic health record systems. Phyxiom's launch marks a significant milestone in Ireland's healthtech landscape, highlighting Irish innovation on the global healthcare stage. Those interested in learning more about Phyxiom, can visit the website here: About RCSI University of Medicine and Health Sciences RCSI University of Medicine and Health Sciences is ranked first in the world for its contribution to UN Sustainable Development Goal 3, Good Health and Well-being, in the Times Higher Education (THE) University Impact Rankings 2025. Founded in 1784 as the Royal College of Surgeons in Ireland with responsibility for training surgeons in Ireland, today RCSI is an innovative, not-for-profit, international university exclusively focused on driving improvements in human health worldwide through education, research and engagement. RCSI is among the top 300 universities worldwide in the World University Rankings (2025) and has been awarded Athena Swan Bronze accreditation for positive gender practice in higher education. In 2026, RCSI will open a new public engagement space, dedicated to health and well-being, at 118 St Stephen's Green in Dublin city centre. The space is designed to engage the public in dialogue about living longer, healthier and happier lives through dynamic events and exhibitions. Our aim is to bridge the gap between health sciences research, professional expertise, and public understanding, empowering people to make informed decisions about their health. Visit the RCSI MyHealth Expert Directory to find the details of our experts across a range of healthcare issues and concerns. Recognising their responsibility to share their knowledge and discoveries to empower people with information that leads them to better health, these clinicians and researchers are willing to engage with the media in their area of expertise. View source version on Contacts phyxiom@ or call Lewis Oakley or Kirsty Leighton on +44 20 3637 7310 Sign in to access your portfolio
